NCT04065269View on ClinicalTrials.gov

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

PHASE2RecruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

November 27, 2019

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Gynaecological Cancers
Interventions
DRUG

Ceralasertib

ATR inhibitor

DRUG

Olaparib

PARP inhibitor

DRUG

Durvalumab

Anti-PD-L1 immunotherapy

Trial Locations (9)

K1H 8L6

ACTIVE_NOT_RECRUITING

The Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

ACTIVE_NOT_RECRUITING

Princess Margaret Cancer Centre, Toronto

H2X 3E4

ACTIVE_NOT_RECRUITING

University of Montreal Hospital Centre, Montreal

BA1 3NG

RECRUITING

Royal United Hospital, Bath

Unknown

RECRUITING

Western General Hospital, Edinburgh

RECRUITING

The Beatson, Glasgow

ACTIVE_NOT_RECRUITING

Imperial College NHS Trust, London

RECRUITING

The Christie, Manchester

SW3 6JJ

RECRUITING

The Royal Marsden NHS Foundation Trust, London

Sponsors
All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Institute of Cancer Research, United Kingdom

OTHER